Market Overview

UPDATE: Bank of America Reiterates Neutral Rating, Raises PT on Idenix Pharmaceuticals

Related IDIX
What Investors Are Watching For In Regulus Therapeutics' Next Data Release
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

In a report published Monday, Bank of America reiterated its Neutral rating on Idenix Pharmaceuticals (NASDAQ: IDIX), and slightly raised its price target from $6.00 to $7.00.

Bank of America noted, “Today IDIX announced a non-exclusive collaboration with JNJ to initiate Phase 2 all-oral combination studies for the treatment of HCV for the company's early stage NS5a inhibitor. While the news is consistent with early-Jan feedback from the company of an imminent transaction, it provides IDIX with a critical first step forward to advance IDX719, which had taken a backseat in 2012 during multiple program setbacks for the company's HCV nucs. The first study expected to start in 1Q13 will evaluate IDX719 with JNJ's protease inhibitor TMC-435 and RBV dosed for 12 weeks and will be initiated following a standard drug-drug interaction study; a second combo study with JNJ's non-nuc should follow. These data will provide the first 12-week safety data for IDX719, and will establish whether the IDIX/JNJ combo has any benefits over the similar BMY/JNJ combo already under investigation. If positive, IDX719 could be an important value driver for the IDIX, which is currently primarily valued on the potential royalty stream from GILD's GS-7977. Based on today's news, we are increasing our PO from $6 to $7 to increase IDX719 value per share from $2 to $3; however we see impressive potential upside to valuation on positive results.”

Idenix Pharmaceuticals closed on Friday at $5.48.

Latest Ratings for IDIX

Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (IDIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters